Drugs / FAP-targeted immunosuppressive CAR-DCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07505199 | May 2026 → Apr 2028 expected | cardiomyopathy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FAP-targeted immunosuppressive CAR-DCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07505199 ↗ |
| Known as | FAP iCDC | “Administration of autologus FAP iCDC” NCT07505199 ↗ |
| Known as | iCDC | “This study evaluates a novel therapeutic strategy using fibroblast activation protein (FAP)-targeted autologous immunosuppressive chimeric antigen receptor dendritic cell...” NCT07505199 ↗ |
| Modality | Cell therapy | “autologous immunosuppressive chimeric antigen receptor dendritic cell (CAR-DC) therapy” NCT07505199 ↗ |
| Route | Intravenous | “Each subject receives FAP-targeted immunosuppressive CAR-DCs by intravenous infusion after enrollment.” NCT07505199 ↗ |
| Target | FAP | “FAP-targeted autologous immunosuppressive chimeric antigen receptor dendritic cell (CAR-DC) therapy” NCT07505199 ↗ |